Dr. Zack Scott is a General Partner and Co-Head of the healthcare investment team at Norwest. An experienced healthcare investor, Zack currently serves on the board of directors for Apreo Health, Cytovale, Galvanize Therapeutics, Nectero Medical, SetPoint Medical and ShiraTronics. He is a board observer at VenoStent and was previously on the board of Vertos Medical (acquired by Stryker).

Earlier in his career, Zack served on the board of directors for Cianna Medical, Coherex Medical, Evidation Health, Providence Medical Technology, Respicardia, Spiration, and Syapse.

Prior to joining Norwest, Zack was the co-founder and managing partner of Revelation Partners, a dedicated secondary investor specializing in shareholder liquidity and growth capital for healthcare companies. During his time at Revelation Partners, he made notable investments in Omada Health (IPO), iRhythm Technologies (IPO), SetPoint Medical, and Respicardia (acquired by Zoll Medical).

Before working in private equity, Zack was a General Surgery resident at Oregon Health & Science University in Portland, Oregon. He earned his M.D. from the University of Texas Health Science Center at San Antonio where he was a member of the AOA Medical Honors Society, and subsequently earned an M.B.A. with a specialized certificate in Health Sector Management from The Fuqua School of Business at Duke University where he was a Fuqua Scholar.